WGS GeneDx Holdings Corp.
FY2025 10-K
GeneDx Holdings Corp. (WGS) filed its fiscal year 2025 10-K annual report with the SEC on Feb 23, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business model: Provider of clinical exome and genome sequencing diagnostics powered by proprietary GeneDx Infinity™ rare disease dataset
- • New emphasis on rapid and ultraRapid genomes, medium/long-read sequencing, and multimodal genomic analysis expansion in 2025
Management Discussion & Analysis
- • Revenue and profitability details not provided in the excerpt
- • No segment performance data disclosed
Risk Factors
- • Regulatory risk: $42M settlement agreement with third-party payor for alleged overpayments to Legacy Sema4, $2M remaining payments as of Dec 31, 2025
- • Macroeconomic risk: reliance on reimbursement approvals from commercial and Medicaid payors, with 18% average reimbursement rate increase in 2025 impacting revenue
Get deeper insights on GeneDx Holdings Corp.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.